About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 449 record(s)
Req # A-2023-000155
The disclosable inspection document(s) listing the Inspector’s detailed observations, conditions found, and any follow-up expected by Health Canada for the human drugs drug establishment licence Good Manufacturing Practices (GMP) inspection of the…Organization: Health Canada
September 2023
Req # A-2023-000162
The safety summary reports of the hematological monitoring for GEN-Clozapine-associated neutropenia/agranulocytosis. Manufacturer: Mylan. The request references all marketed strengths of GEN-Clozapine tablets (Drug Indentification Numbers (DIN),…Organization: Health Canada
September 2023
Req # A-2023-000313
The licensed indications for use for MicroTheurapeutic‘s Axium Embolization Coils on Medical Device License 63475 that Health Canada has on file for this license.Organization: Health Canada
September 2023
Req # A-2023-000365
All notice of allegation (NOA) filing dates as outlined under sections 5(2.1)(c)(ii), (iii), and (iv) of the Patented Medicines (Notice of Compliance) Regulations, as well as the date in which the NOA was responded to by the first person for the…Organization: Health Canada
September 2023
Req # A-2023-000384
Drafts and finalized version of the report on Sex and Gender-Based Analysis Plus (SGBA Plus) in Medical Devices presented to the Director General of Medical Devices Directorate (MDD) by the Scientific Advisory Committee on Health Products for Women.Organization: Health Canada
September 2023
Req # A-2023-000441
The initial cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-06-23 for the medicinal ingredient Mesalazine. The…Organization: Health Canada
September 2023
Req # A-2023-000442
The initial cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-06-23 for the medicinal ingredient Amphotericin B…Organization: Health Canada
September 2023
Req # A-2023-000507
Obtain all non-confidential documents for the following medical device licence application approved by Health Canada in 2016: Licence No.: 97381; Type: System; Device class: 2; Device first issue date 2016-07-27; Licence name: LUCAS 3 CHEST…Organization: Health Canada
September 2023
Req # A-2023-000537
All correspondence between Health Canada and the College of Physicians and Surgeons of Ontario, and Health Canada (HC) and the Ontario College of Pharmacists (OPC) related to the use Ivermectin for COVID-19. Date range January 1 2020 to May 31 2023…Organization: Health Canada
September 2023
Req # A-2023-000570
With respect to the New Drug Submission for ABSORICA LD, portions of the New Drug Submission that relate to Sun Pharmaceuticals Industries Limited’s ownership, agreement, or contractual rights to the data in the Phase III study referenced in section…Organization: Health Canada
September 2023